{"preliminary_commentary":{"by_channel":{"x_thread":24,"youtube":9,"podcast":5,"bluesky_thread":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06364631\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CARE1","nct_id":"NCT06364631","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=care1-nct06364631. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CARE1","arms":[{"description":"Nivolumab (3 mg/kg infusion, every 3 weeks) x 4 doses + ipilimumab (1 mg/kg infusion, every 3 weeks) x 4 doses. At the end of the 4 injections carried out 21 days apart and in the absence of limiting side effects or progression justifying the cessation of the treatment according to the investigating doctor, maintenance treatment with nivolumab will be continued, at a rate of one injection every 2 weeks at a dose of 240 mg or every 4 weeks at a dose of 480 mg depending on the choice of the investigating doctor. Nivolumab will be administered for a maximum of 2 years.\n\nPatients are required to receive all four doses of NIVO+IPI before beginning NIVO monotherapy except for ipilimumab-induced toxicity compatible with nivolumab maintenance.","label":"Arm A: ICI - ICI Combination","type":"OTHER"},{"description":"Investigator's choice between:\n\n* Axitinib (5 mg oral twice a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks).\n* Cabozantinib (40 mg oral, once a day away from meals) + nivolumab infusion (480 mg flat dose every 4 weeks)\n* Lenvatinib (20 mg oral, once a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks)","label":"Arm B: VEGFR-TKI- ICI arm (axitinib + pembrolizumab)","type":"OTHER"}],"collaborators":["European Commission","CRIS Cancer Foundation","National Cancer Institute, France","Rennes University Hospital","University Hospital, Essen","Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron","The Netherlands Cancer Institute","Servicio Madrileño de Salud, Madrid, Spain","Hospital Universitario 12 de Octubre","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Medical University of Vienna","FAKULTNI NEMOCNICE OLOMOUC","International Kidney Cancer Coalition","Association pour la Recherche sur les Tumeurs du Rein","Resilience","PRIMAA","Queen Mary University of London"],"completion_date":{"date":"2032-05-05","type":"ESTIMATED"},"conditions":["Metastatic Kidney Cancer","Metastatic Kidney Carcinoma"],"enrollment":{"count":1250,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["OPDIVO"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["YERVOY"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["KEYTRUDA"],"type":"DRUG"},{"name":"Cabozantinib","otherNames":["CABOMETYX"],"type":"DRUG"},{"name":"Axitinib","otherNames":["INLYTA"],"type":"DRUG"},{"name":"Lenvatinib","otherNames":["LENVIMA"],"type":"DRUG"}],"last_update":"2025-01-16","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","official_title":"First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-05-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS).","timeFrame":"At end of study, 97 months"}],"references":[],"start_date":{"date":"2024-04-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"CARE1 Pragmatic Clinical Trial","url":"https://clinicaltrials.gov/study/NCT06364631"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/care1-nct06364631"}